ÂÜÀòÂÒÂ×

Alan has over 20 years of experience across healthcare investment banking, private equity and venture capital investments in Asia/China. He is Managing Partner at GT Healthcare Capital Group, a private equity fund focusing on cross border healthcare investments founded in 2015. Alan currently serves as a Board member and Audit Committee Chairman of CSPC Pharmaceutical Group (1093.hk, a Hang Seng Index constituent company); he is also a Board member of I-Mab Biopharma Group (Nasdaq: IMAB), a clinical-stage biopharma. Besides, Alan serves as a panel member of the Innovation and Technology Fund of the Hong Kong SAR Government. Alan was a senior adviser to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE: SCR, privatized in Dec 2013, when Alan was Chairman of the Special Committee on the Board of Directors). Alan has been the head of Investment Banking, M&A, Investment director, and managing partner at multiple firms responsible for healthcare investments in Asia. Alan is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst (CFA) designation. He is an associate member of the Hong Kong Institute of Financial Analysts and a member of the American Institute of Certified Public Accountants. Alan received his Bachelor’s degree in Psychology from the Chinese University of Hong Kong and a Master’s degree in Management from Columbia Business School in New York.